Themis Medicare Ltd Technical Momentum Shifts to Bullish Amid Mixed Market Returns

Technical Trend Upgrade and Price Movement

Themis Medicare’s technical trend has recently transitioned from mildly bullish to bullish, reflecting a strengthening in price momentum. The stock closed at ₹112.05 on 9 July 2026, down from the previous close of ₹116.65, with an intraday range between ₹111.15 and ₹119.25. While the day’s decline of 3.94% may appear concerning, it is important to consider the broader technical context and longer-term trends.

The 52-week price range remains wide, with a high of ₹147.99 and a low of ₹65.00, indicating significant volatility over the past year. The current price sits closer to the lower half of this range, suggesting potential room for recovery if bullish momentum sustains.

MACD and Moving Averages Signal Strengthening Momentum

The Moving Average Convergence Divergence (MACD) indicator presents a bullish signal on the weekly timeframe, while the monthly MACD remains mildly bullish. This suggests that short-term momentum is gaining strength, supported by positive crossover patterns and increasing momentum in recent weeks. The daily moving averages further reinforce this view, with the stock trading above key averages, indicating a bullish short-term trend.

Such alignment between MACD and moving averages is often interpreted as a confirmation of upward price momentum, which could attract technical traders and momentum investors looking for entry points.

RSI and Bollinger Bands Reflect Mixed Sentiment

The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no clear signal, hovering in neutral territory. This suggests that the stock is neither overbought nor oversold, leaving room for directional movement without immediate risk of reversal due to extreme conditions.

Bollinger Bands present a nuanced picture: mildly bullish on the weekly timeframe but mildly bearish on the monthly. The weekly mild bullishness indicates recent price strength relative to volatility, while the monthly mild bearishness may reflect longer-term consolidation or resistance pressures. Investors should monitor these bands closely for potential breakout or breakdown signals.

Additional Technical Indicators: KST, OBV, and Dow Theory

The Know Sure Thing (KST) indicator is bullish on the weekly chart and mildly bullish on the monthly, reinforcing the positive momentum narrative. This momentum oscillator’s readings suggest that price acceleration is improving, which could support further gains if sustained.

On-Balance Volume (OBV) shows no clear trend on the weekly timeframe but is bullish on the monthly, indicating that longer-term accumulation may be underway despite short-term volume fluctuations. This divergence between weekly and monthly OBV trends warrants attention, as volume often precedes price moves.

Dow Theory analysis reveals no definitive trend on either weekly or monthly charts, signalling that the stock has yet to establish a clear directional trend according to this classical method. This underscores the importance of corroborating signals from other technical tools before making decisive investment decisions.

Comparative Performance Against Sensex

Examining Themis Medicare’s returns relative to the benchmark Sensex provides valuable context for its technical developments. Over the past week, the stock outperformed the Sensex with a 1.31% gain versus the index’s 0.54% decline. Over one month, Themis Medicare’s return of 7.90% notably exceeded the Sensex’s 4.05% rise, and year-to-date gains stand at 11.33% compared to the Sensex’s negative 10.23%.

However, longer-term performance paints a more mixed picture. The stock has declined 13.77% over the past year, underperforming the Sensex’s 8.61% loss, and over three years, it has fallen 25.83% while the Sensex gained 17.19%. Conversely, over five and ten years, Themis Medicare has outpaced the Sensex with returns of 50.67% and 104.32% respectively, compared to the Sensex’s 45.53% and 182.02%.

This mixed relative performance highlights the stock’s volatility and cyclical nature within the pharmaceuticals and biotechnology sector, emphasising the need for careful timing and technical analysis in investment decisions.

Mojo Score and Grade Upgrade Reflect Improving Outlook

Themis Medicare’s MarketsMOJO score currently stands at 60.0, categorised as a Hold rating. This represents an upgrade from a previous Sell grade as of 30 June 2026, signalling an improving outlook based on a combination of fundamental and technical factors. The micro-cap classification highlights the stock’s smaller market capitalisation, which often entails higher volatility but also potential for outsized gains.

Investors should weigh this upgraded rating alongside the mixed technical signals and recent price volatility. The Hold grade suggests a cautious approach, favouring monitoring for confirmation of sustained bullish momentum before committing significant capital.

Conclusion: Navigating Themis Medicare’s Technical Landscape

Themis Medicare Ltd’s recent technical parameter changes indicate a shift towards a more bullish momentum profile, supported by positive MACD readings, daily moving averages, and KST indicators. However, neutral RSI signals and mixed Bollinger Band readings advise prudence, as the stock remains susceptible to volatility and lacks a clear Dow Theory trend confirmation.

Relative performance against the Sensex reveals short-term outperformance but longer-term underperformance, underscoring the importance of timing and technical analysis in managing exposure to this pharmaceutical micro-cap. The upgrade in Mojo Grade from Sell to Hold further reflects a cautiously optimistic stance.

For investors considering Themis Medicare, the current technical environment suggests potential for upside if bullish momentum continues to build, but also the need for vigilance given the stock’s volatility and mixed signals. Monitoring key technical indicators and volume trends will be essential to gauge the sustainability of this momentum shift.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →